Study of Circulating Tumoral DNA in Metastatic Choroidal Melanoma

Development and Validation of a Circulating Tumor DNA Detection Technique in Patients With Metastatic Choroidal Melanoma

Circulating tumor DNA detection and quantification in patients with metastatic choroidal melanoma.

Technique development: In first step, the different available techniques will be evaluated for specificity and sensibility using serial dilutions of cell lines with or without GNAQ mutation.

Validation: The tumor DNA detection rate will be estimated from metastatic uveal patient's blood. The investigators will study 40 patients to obtain at least 15 patients bearing a GNAQ mutation in the primitive tumor or in metastasis. With those 15 patients, the investigators will determinate the most sensitive technique and the best cost/efficiency ratio.

Inclusion Criteria:

• Age > or = 18 years.
• Patient with a metastatic choroidal melanoma.
• Patient with tumor or metastasis available for GNAQ (Guanine nucleotide blinding protein) status characterization.
• Patient able to stand a blood collection.
• Signed written informed consent approved by competent authority and ethic committee.

Exclusion Criteria:

• Patient without social protection/insurance.
• Current pregnancy and lactation.
• All social, medical, psychological, situations making the study impossible.
• Person deprived of liberty.